Xuejie J. Zhang is an Associate Professor in the Department of Medicine at the University of Chicago, where he works as a health economist and health services researcher. His research focuses on the intersection of economic forces and health outcomes, with particular emphasis on medication adherence, healthcare financing, and policy implications. Dr. Zhang's research interests span several critical areas in health economics and services research. He has extensively studied cost-related medication non-adherence among Medicare beneficiaries, particularly those with chronic conditions like diabetes and heart failure. His work also addresses Medicare Part D policy, pharmaceutical pricing, and disparities in access to quality care for vulnerable populations. Using innovative methodological approaches, he applies big data analytics and machine learning techniques to claims data to identify patterns and develop interventions that improve patient outcomes while addressing cost concerns. His publication record shows consistent productivity with over 50 publications spanning more than two decades. His recent work (2020-2025) demonstrates continued focus on medication adherence during the pandemic, value-based payment models for innovative therapies, and the development of integrated datasets for patient-centered outcomes research. His articles frequently appear in high-impact journals including JAMA Network Open, Medical Care, and PLoS One, reflecting the significance of his contributions to health services research. Recognized for exceptionally fine quality of reviewing for Annals of Internal Medicine Rated within Top 5% of reviewers as "Outstanding Reviewers for Health Services Research" Among Top 4% of peer reviewers for JAMA Network Open Mentored students whose research projects have won accolades at university training awards and national/international conferences Dr. Zhang serves as a reviewer for more than four dozen professional journals, demonstrating his standing in the academic community. His research has significant policy implications, particularly regarding Medicare beneficiaries and pharmaceutical pricing. While specific grant information isn't detailed in the provided text, his extensive publication record suggests successful funding for his research programs. His work bridges clinical practice, health policy, and economic analysis to address critical challenges in healthcare delivery and financing.
